Delivery Order SPE2DB22D9112-SPE2DB25FTKRF
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $32,308.74 to DMS Pharmaceutical Group Inc. on September 23, 2025, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, with an ultimate completion date of October 15, 2025, is to be performed in Park Ridge, Illinois, where the vendor is headquartered. The award carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its status as a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $32,499.90 to DMS Pharmaceutical Group Inc. on August 26, 2025, for the supply of Stelara 90 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order with a firm fixed-price contract structure and ultimate completion date of September 17, 2025. The contract carries no set-aside designation, allowing the vendor to compete directly...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,249.95 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The award, issued on August 14, 2025, with an ultimate completion date of September 5, 2025, carries a firm fixed-price arrangement with no set-aside designation. This delivery order represents a single transaction under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This firm fixed-price delivery order, valued at $16,249.95, was awarded on September 2, 2025, with an ultimate completion date of September 23, 2025. The contract does not utilize a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency (DLA) awarded a $16,249.95 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on July 22, 2025, for the supply of Stelara 90 mg/ml syringes. The award carries an ultimate completion date of August 12, 2025, and involves no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its facility in Park Ridge. This delivery order falls under the...
- The Defense Logistics Agency (DLA) issued a delivery order valued at $32,499.90 to DMS Pharmaceutical Group Inc. for Stelara 90 mg/ml syringes, with an ultimate completion date of August 4, 2025. This firm fixed-price delivery order was awarded on July 14, 2025, without a set-aside designation, leveraging the contractor's status as a woman-owned small business. The product will be delivered to Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its headquarters and primary operations....
- The Defense Logistics Agency awarded a $65,000 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. This delivery order, issued on July 31, 2025, represents an individual task order under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA valued at $500 million and extending through November 2026. The delivery order carries an...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,249.95 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/ml syringes. The contract, designated as a firm fixed-price delivery order, was awarded on September 15, 2025, with an ultimate completion date of October 6, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group to...
- On August 18, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $32,499.90 to DMS Pharmaceutical Group Inc. for the supply of Stelara 90 mg/ml syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery order at its facility in Park Ridge, IL. This award represents a firm fixed-price delivery order under the company's larger Indefinite Delivery Contract with the DLA, valued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $97,499.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 90 mg/mL syringes. This firm fixed-price delivery order, issued on July 28, 2025, with an ultimate completion date of August 18, 2025, represents a tactical purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA valued at $500...
- SPE2DB22D9112Indefinite Delivery Contract
- SPE2DB22D9112-SPE2DB25FTKRFDelivery Order
The Defense Logistics Agency (DLA) awarded a $65,000 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on September 24, 2025, for the supply of Stelara 90 mg/ml syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its Park Ridge facility with an ultimate completion date of October 16, 2025. This delivery order was not issued under any set-aside designation, allowing the vendor to compete on an unrestricted basis within the federal marketplace. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA valued at $500 million through November 2026. The company has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging this master contract vehicle to provide firm fixed-price delivery orders for pharmaceuticals and medical supplies to Department of Defense healthcare facilities worldwide. Stelara, an immunosuppressive biologic medication, represents one of many specialized pharmaceutical products the vendor delivers to support military health system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $65.0k | 9/24/25 |